{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:08:27Z","timestamp":1778936907315,"version":"3.51.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,16]]},"DOI":"10.7759\/cureus.108967","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:29:31Z","timestamp":1778934571000},"source":"Crossref","is-referenced-by-count":0,"title":["Belzutifan in Von Hippel-Lindau Syndrome and Renal Cell Carcinoma: Mechanisms, Clinical Evidence, and Future Directions"],"prefix":"10.7759","author":[{"given":"Jooah","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heena","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharib","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha Pillai","family":"Vinod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riya","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divyansh","family":"Vats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inamullah","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2024.2436433","article-title":"Targeting HIF-2\u03b1: the role of belzutifan in clear cell renal carcinoma management","volume":"18","author":"Vald\u00e9s A","year":"2025","unstructured":"Vald\u00e9s A, Pizarro G, Gonz\u00e1lez-Montero J, Rojas C, Burotto M. Targeting HIF-2\u03b1: the role of belzutifan in clear cell renal carcinoma management. Expert Rev Clin Pharmacol. 2025, 18:17-27. 10.1080\/17512433.2024.2436433","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14164059","article-title":"Epidemiology and prevention of renal cell carcinoma","volume":"14","author":"Makino T","year":"2022","unstructured":"Makino T, Kadomoto S, Izumi K, Mizokami A. Epidemiology and prevention of renal cell carcinoma. Cancers (Basel). 2022, 14:10.3390\/cancers14164059","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251317846","article-title":"Belzutifan for the treatment of renal cell carcinoma","volume":"17","author":"Wu X","year":"2025","unstructured":"Wu X, Lazris D, Wong R, Tykodi SS. Belzutifan for the treatment of renal cell carcinoma. Ther Adv Med Oncol. 2025, 17:17588359251317846. 10.1177\/17588359251317846","journal-title":"Ther Adv Med Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1054","article-title":"FDA approval summary: Belzutifan for von Hippel-Lindau disease-associated tumors","volume":"28","author":"Fallah J","year":"2022","unstructured":"Fallah J, Brave MH, Weinstock C, et al.. FDA approval summary: Belzutifan for von Hippel-Lindau disease-associated tumors. Clin Cancer Res. 2022, 28:4843-8. 10.1158\/1078-0432.CCR-22-1054","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00099-3","article-title":"Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study","volume":"26","author":"Srinivasan R","year":"2025","unstructured":"Srinivasan R, Iliopoulos O, Beckermann KE, et al.. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol. 2025, 26:571-82. 10.1016\/S1470-2045(25)00099-3","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2120403119","article-title":"Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway","volume":"119","author":"Stransky LA","year":"2022","unstructured":"Stransky LA, Vigeant SM, Huang B, et al.. Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proc Natl Acad Sci U S A. 2022, 119:e2120403119. 10.1073\/pnas.2120403119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2012.04.032","article-title":"Systemic VHL gene functions and the VHL disease","volume":"586","author":"Bader HL","year":"2012","unstructured":"Bader HL, Hsu T. Systemic VHL gene functions and the VHL disease. FEBS Lett. 2012, 586:1562-9. 10.1016\/j.febslet.2012.04.032","journal-title":"FEBS Lett"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/genes16010006","article-title":"Hypoxia-inducible factor in renal cell carcinoma: from molecular insights to targeted therapies","volume":"16","author":"Roviello G","year":"2024","unstructured":"Roviello G, De Gennaro I, Vascotto I, et al.. Hypoxia-inducible factor in renal cell carcinoma: from molecular insights to targeted therapies. Genes (Basel). 2024, 16:10.3390\/genes16010006","journal-title":"Genes (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch E","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O, et al.. Belzutifan for renal cell carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021, 385:2036-46. 10.1056\/NEJMoa2103425","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14171909","article-title":"Genetics, pathophysiology, and current challenges in von Hippel-Lindau disease therapeutics","volume":"14","author":"G\u00f3mez-Virgilio L","year":"2024","unstructured":"G\u00f3mez-Virgilio L, Velazquez-Paniagua M, Cuazozon-Ferrer L, et al.. Genetics, pathophysiology, and current challenges in von Hippel-Lindau disease therapeutics. Diagnostics (Basel). 2024, 14:10.3390\/diagnostics14171909","journal-title":"Diagnostics (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.12.011","article-title":"The road to systemic therapy in von Hippel-Lindau (VHL) disease: are we there yet?","volume":"182","author":"Shepherd ST","year":"2023","unstructured":"Shepherd ST, Drake WM, Turajlic S. The road to systemic therapy in von Hippel-Lindau (VHL) disease: are we there yet?. Eur J Cancer. 2023, 182:15-22. 10.1016\/j.ejca.2022.12.011","journal-title":"Eur J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0283","article-title":"LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma","volume":"19","author":"Choueiri TK","year":"2023","unstructured":"Choueiri TK, Powles T, Voss MH, et al.. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. Future Oncol. 2023, 19:2631-40. 10.2217\/fon-2023-0283","journal-title":"Future Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-020-04712-5","article-title":"Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment","volume":"36","author":"Klingler JH","year":"2020","unstructured":"Klingler JH, Gl\u00e4sker S, Bausch B, et al.. Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment. Childs Nerv Syst. 2020, 36:2537-52. 10.1007\/s00381-020-04712-5","journal-title":"Childs Nerv Syst"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000539434","article-title":"Belzutifan in individuals with von Hippel-Lindau retinal hemangioblastomas: institutional experience and review of the literature","volume":"10","author":"Jamshidi F","year":"2024","unstructured":"Jamshidi F, Lozano L, Tucker B, et al.. Belzutifan in individuals with von Hippel-Lindau retinal hemangioblastomas: institutional experience and review of the literature. Ocul Oncol Pathol. 2024, 10:154-61. 10.1159\/000539434","journal-title":"Ocul Oncol Pathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157094","article-title":"Belzutifan-associated hypoxia: a review of the novel therapeutic, proposed mechanisms of hypoxia, and management recommendations","volume":"26","author":"Kucharczyk J","year":"2025","unstructured":"Kucharczyk J, Bhatt A, Bauer L, Economides M. Belzutifan-associated hypoxia: a review of the novel therapeutic, proposed mechanisms of hypoxia, and management recommendations. Int J Mol Sci. 2025, 26:10.3390\/ijms26157094","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0679","article-title":"Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond","volume":"20","author":"Curry L","year":"2024","unstructured":"Curry L, Soleimani M. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond. Future Oncol. 2024, 20:1251-66. 10.2217\/fon-2023-0679","journal-title":"Future Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.122.000525","article-title":"Structural basis for the allosteric inhibition of hypoxia-inducible factor (HIF)-2 by belzutifan","volume":"102","author":"Ren X","year":"2022","unstructured":"Ren X, Diao X, Zhuang J, Wu D. Structural basis for the allosteric inhibition of hypoxia-inducible factor (HIF)-2 by belzutifan. Mol Pharmacol. 2022, 102:10.1124\/molpharm.122.000525","journal-title":"Mol Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri TK","year":"2021","unstructured":"Choueiri TK, Bauer TM, Papadopoulos KP, et al.. Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021, 27:802-5. 10.1038\/s41591-021-01324-7","journal-title":"Nat Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13028","article-title":"Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling","volume":"12","author":"Marathe DD","year":"2023","unstructured":"Marathe DD, Jauslin PM, Kleijn HJ, et al.. Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling. CPT Pharmacometrics Syst Pharmacol. 2023, 12:1499-510. 10.1002\/psp4.13028","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref20","unstructured":"ClinicalTrials.gov. Study of MK-6482 in participants with advanced solid tumors (MK-6482-001). ClinicalTrials.gov identifier. NCT03401788. (2023). Accessed: January 5, 2026: https:\/\/clinicaltrials.gov\/study\/NCT03401788."},{"key":"ref21","unstructured":"U.S. Food and Drug Administration. Welireg (belzutifan) prescribing information. (2024). Accessed. January 5, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215383Orig1s007lbl.pdf."},{"key":"ref22","unstructured":"U.S. Food and Drug Administration. FDA approves belzutifan for advanced renal cell carcinoma. (2026). Accessed. January 5, 2026: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-advanced-renal-cell-carcinoma."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus Everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri TK","year":"2024","unstructured":"Choueiri TK, Powles T, Peltola K, et al.. Belzutifan versus Everolimus for advanced renal-cell carcinoma. N Engl J Med. 2024, 391:710-21. 10.1056\/NEJMoa2313906","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00389-9","article-title":"Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study","volume":"25","author":"Iliopoulos O","year":"2024","unstructured":"Iliopoulos O, Iversen AB, Narayan V, et al.. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2024, 25:1325-36. 10.1016\/S1470-2045(24)00389-9","journal-title":"Lancet Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-023-04496-z","article-title":"The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience","volume":"165","author":"Zamarud A","year":"2023","unstructured":"Zamarud A, Marianayagam NJ, Park DJ, Yener U, Yoo KH, Meola A, Chang SD. The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience. J Neurooncol. 2023, 165:373-9. 10.1007\/s11060-023-04496-z","journal-title":"J Neurooncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-023-04395-3","article-title":"Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience","volume":"164","author":"Neth BJ","year":"2023","unstructured":"Neth BJ, Webb MJ, White J, Uhm JH, Pichurin PN, Sener U. Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience. J Neurooncol. 2023, 164:239-47. 10.1007\/s11060-023-04395-3","journal-title":"J Neurooncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00649-1","article-title":"Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK- 003): an open-label, single-arm, phase 2 study","volume":"26","author":"Choueiri TK","year":"2025","unstructured":"Choueiri TK, Merchan JR, Figlin R, et al.. Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK- 003): an open-label, single-arm, phase 2 study. Lancet Oncol. 2025, 26:64-73. 10.1016\/S1470-2045(24)00649-1","journal-title":"Lancet Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1199","article-title":"FDA approval summary: Belzutifan for patients with advanced renal cell carcinoma","volume":"30","author":"Fallah J","year":"2024","unstructured":"Fallah J, Heiss BL, Joeng HK, et al.. FDA approval summary: Belzutifan for patients with advanced renal cell carcinoma. Clin Cancer Res. 2024, 30:5003-8. 10.1158\/1078-0432.CCR-24-1199","journal-title":"Clin Cancer Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113434","article-title":"Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: extended 41-month follow-up in the clear cell renal cell carcinoma cohort","volume":"196","author":"Jonasch E","year":"2024","unstructured":"Jonasch E, Bauer TM, Papadopoulos KP, et al.. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer. 2024, 196:113434. 10.1016\/j.ejca.2023.113434","journal-title":"Eur J Cancer"},{"key":"ref30","unstructured":"ClinicalTrials.gov. Belzutifan (MK-6482) for the treatment of advanced pheochromocytoma\/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced gastrointestinal stromal tumor (wild-type GIST), or solid tumors with HIF-2\u03b1-related genetic alterations (MK-6482-015). ClinicalTrials.gov identifier. NCT04195750. (2026). https:\/\/clinicaltrials.gov\/study\/NCT04195750."},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4173","article-title":"Study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors","volume":"40","author":"Kelley RK","year":"2022","unstructured":"Kelley RK, Van Cutsem E, Lee MS, et al.. Study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors. J Clin Oncol. 2022, 40:669.","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06890-6","article-title":"Independence of HIF1a and androgen signaling pathways in prostate cancer","volume":"20","author":"Tran MG","year":"2020","unstructured":"Tran MG, Bibby BA, Yang L, et al.. Independence of HIF1a and androgen signaling pathways in prostate cancer. BMC Cancer. 2020, 20:469. 10.1186\/s12885-020-06890-6","journal-title":"BMC Cancer"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110051","article-title":"Belzutifan, a potent HIF2\u03b1 inhibitor, in the Pacak-Zhuang syndrome","volume":"385","author":"Kamihara J","year":"2021","unstructured":"Kamihara J, Hamilton KV, Pollard JA, et al.. Belzutifan, a potent HIF2\u03b1 inhibitor, in the Pacak-Zhuang syndrome. N Engl J Med. 2021, 385:2059-65. 10.1056\/NEJMoa2110051","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31371","article-title":"Pediatric patients with von Hippel-Lindau and hemangioblastomas treated successfully with belzutifan","volume":"72","author":"Duan E","year":"2025","unstructured":"Duan E, Robinson M, Davis C, et al.. Pediatric patients with von Hippel-Lindau and hemangioblastomas treated successfully with belzutifan. Pediatr Blood Cancer. 2025, 72:e31371. 10.1002\/pbc.31371","journal-title":"Pediatr Blood Cancer"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2592","article-title":"Belzutifan for von Hippel-Lindau disease: pancreatic lesion population of the Phase 2 Litespark-004 study","volume":"30","author":"Else T","year":"2024","unstructured":"Else T, Jonasch E, Iliopoulos O, et al.. Belzutifan for von Hippel-Lindau disease: pancreatic lesion population of the Phase 2 Litespark-004 study. Clin Cancer Res. 2024, 30:1750-7. 10.1158\/1078-0432.CCR-23-2592","journal-title":"Clin Cancer Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00032-4","article-title":"Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK- 005): patient-reported outcomes from a randomised, open-label, phase 3 trial","volume":"26","author":"Powles T","year":"2025","unstructured":"Powles T, Choueiri TK, Albiges L, et al.. Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK- 005): patient-reported outcomes from a randomised, open-label, phase 3 trial. Lancet Oncol. 2025, 26:491-502. 10.1016\/S1470-2045(25)00032-4","journal-title":"Lancet Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2338","article-title":"Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma","volume":"35","author":"Agarwal N","year":"2024","unstructured":"Agarwal N, Brugarolas J, Ghatalia P, et al.. Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. Ann Oncol. 2024, 35:1148-56. 10.1016\/j.annonc.2024.08.2338","journal-title":"Ann Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504964","article-title":"Belzutifan for advanced pheochromocytoma or paraganglioma","volume":"393","author":"Jimenez C","year":"2025","unstructured":"Jimenez C, Andreassen M, Durand A, et al.. Belzutifan for advanced pheochromocytoma or paraganglioma. N Engl J Med. 2025, 393:2012-22. 10.1056\/NEJMoa2504964","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1788","article-title":"Phase I LITESPARK- 018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)","volume":"35","author":"Vaishampayan UN","year":"2024","unstructured":"Vaishampayan UN, Rao A, Narayan V, et al.. Phase I LITESPARK- 018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC). Ann Oncol. 2024, 35:1016-695. 10.1016\/j.annonc.2024.08.1788","journal-title":"Ann Oncol"},{"key":"ref40","unstructured":"A study of Belzutifan (MK-6482) in combination with lenvatinib versus cabozantinib for treatment of renal cell carcinoma (MK-6482-011). (2026). https.\/\/clinicaltrials.gov\/study\/NCT04586231."},{"key":"ref41","unstructured":"A study of pembrolizumab (MK-3475) in combination with Belzutifan (MK-6482) and lenvatinib (MK-7902), or pembrolizumab\/Quavonlimab (MK-1308a) in combination with lenvatinib, versus pembrolizumab and lenvatinib, for treatment of advanced clear cell re. (2026).  https.\/\/clinicaltrials.gov\/study\/NCT04736706."},{"key":"ref42","unstructured":"A study of Belzutifan (MK-6482) plus pembrolizumab (MK-3475) versus placebo plus pembrolizumab in participants with clear cell renal cell carcinoma post nephrectomy (MK-6482-022). (2026). https.\/\/clinicaltrials.gov\/study\/NCT05239728."},{"key":"ref43","unstructured":"Phase II trial of single agent Belzutifan or pembrolizumab versus combination as neoadjuvant therapy in clear cell renal cell carcinoma (Blaze). (2026). https.\/\/clinicaltrials.gov\/study\/NCT07187778."},{"key":"ref44","unstructured":"A study of Belzutifan (MK-6482) in combination with palbociclib versus Belzutifan monotherapy in participants with advanced renal cell carcinoma (MK-6482-024\/Litespark-024). (2026). https.\/\/clinicaltrials.gov\/study\/NCT05468697."},{"key":"ref45","unstructured":"Substudy 03B. A study of immune and targeted combination therapies in participants with second line plus (2L+) renal cell carcinoma (MK-3475-03B\/Keymaker-U03). (2026). https:\/\/clinicaltrials.gov\/study\/NCT04626518."},{"key":"ref46","unstructured":"Substudy 03A. A study of immune and targeted combination therapies in participants with first line (1L) renal cell carcinoma (MK-3475-03A). (2026). https:\/\/clinicaltrials.gov\/study\/NCT04626479."},{"key":"ref47","unstructured":"A study of HC-7366 in combination with Belzutifan (Welireg\u2122) in patients with renal cell carcinoma. (2026). https.\/\/clinicaltrials.gov\/study\/NCT06234605."},{"key":"ref48","unstructured":"A study of Belzutifan (MK-6482) as monotherapy and in combination with lenvatinib (E7080\/Mk-7902) with or without pembrolizumab (MK-3475) in China participants with advanced renal cell carcinoma (MK-6482-010). (2026). https.\/\/clinicaltrials.gov\/study\/NCT05030506."},{"key":"ref49","unstructured":"Abema alone or in combo with MK-6482. (2026). https.\/\/clinicaltrials.gov\/study\/NCT04627064."},{"key":"ref50","unstructured":"Pembrolizumab Plus Lenvatinib in combination with Belzutifan in Solid Tumors. (2026). https.\/\/clinicaltrials.gov\/study\/NCT04976634."},{"key":"ref51","unstructured":"Study of Belzutifan (MK-6482) plus Fulvestrant for er+\/HER2- metastatic breast cancer (MK-6482-029\/Litespark-029). (2025). https.\/\/clinicaltrials.gov\/study\/NCT06428396."},{"key":"ref52","unstructured":"Belzutifan in recurrent clear cell carcinoma of gynecologic origin. (2025). https.\/\/clinicaltrials.gov\/study\/NCT06677190."},{"key":"ref53","unstructured":"Study of pembrolizumab (MK-3475) combination therapies in metastatic castration-resistant prostate cancer (MK-3475-365\/keynote-365). (2025). https.\/\/clinicaltrials.gov\/study\/NCT02861573."},{"key":"ref54","unstructured":"A study of Belzutifan (MK-6482) in participants with renal impairment (MK-6482-021). (2026). https.\/\/clinicaltrials.gov\/study\/NCT04994522."},{"key":"ref55","unstructured":"A study of Belzutifan (MK-6482) in participants with hepatic impairment (MK-6482-020). (2026). https.\/\/clinicaltrials.gov\/study\/NCT04995484."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105109","article-title":"Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel-Lindau (VHL) disease-associated haemangioblastoma","volume":"10","author":"Shepherd ST","year":"2025","unstructured":"Shepherd ST, Kelly-Morland C, Drage S, et al.. Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel-Lindau (VHL) disease-associated haemangioblastoma. ESMO Open. 2025, 10:105109. 10.1016\/j.esmoop.2025.105109","journal-title":"ESMO Open"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-024-09906-w","article-title":"Myocarditis following pembrolizumab plus axitinib, and Belzutifan plus lenvatinib for renal cell carcinoma: a case report","volume":"24","author":"Villatore A","year":"2024","unstructured":"Villatore A, Bosi C, Pomaranzi C, et al.. Myocarditis following pembrolizumab plus axitinib, and Belzutifan plus lenvatinib for renal cell carcinoma: a case report. Cardiovasc Toxicol. 2024, 24:1168-73. 10.1007\/s12012-024-09906-w","journal-title":"Cardiovasc Toxicol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-62702-5.00010-X","article-title":"Von Hippel-Lindau disease","volume":"132","author":"Chittiboina P","year":"2015","unstructured":"Chittiboina P, Lonser RR. Von Hippel-Lindau disease. Handb Clin Neurol. 2015, 132:139-56. 10.1016\/B978-0-444-62702-5.00010-X","journal-title":"Handb Clin Neurol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-024-00478-2","article-title":"The importance of patient reported outcomes in oncology clinical trials and clinical practice to inform regulatory and healthcare decision-making","volume":"24","author":"Bellino S","year":"2024","unstructured":"Bellino S, La Salvia A. The importance of patient reported outcomes in oncology clinical trials and clinical practice to inform regulatory and healthcare decision-making. Drugs R D. 2024, 24:123-7. 10.1007\/s40268-024-00478-2","journal-title":"Drugs R D"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-S2-32","article-title":"Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies","volume":"16","author":"Ravaud A","year":"2011","unstructured":"Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist. 2011, 16:32-44. 10.1634\/theoncologist.2011-S2-32","journal-title":"Oncologist"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.v9i3.245","article-title":"Understanding the impact of Belzutifan on treatment strategies for patients with VHL","volume":"9","author":"Arevalo A","year":"2022","unstructured":"Arevalo A, Patel N, Muraki P, et al.. Understanding the impact of Belzutifan on treatment strategies for patients with VHL. J Kidney Cancer VHL. 2022, 9:41-6. 10.15586\/jkcvhl.v9i3.245","journal-title":"J Kidney Cancer VHL"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.15586\/jkc.v12i3.413","article-title":"Hypoxia inducible factor-2\u03b1 (HIF-2\u03b1) pathway inhibitors","volume":"12","author":"Dogra R","year":"2025","unstructured":"Dogra R, Vaishampayan U. Hypoxia inducible factor-2\u03b1 (HIF-2\u03b1) pathway inhibitors. J Kidney Cancer VHL. 2025, 12:1-15. 10.15586\/jkc.v12i3.413","journal-title":"J Kidney Cancer VHL"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2618","article-title":"A Phase I dose-escalation study of the HIF-2 alpha inhibitor DFF332 in patients with advanced clear-cell renal cell carcinoma","volume":"31","author":"Pal SK","year":"2025","unstructured":"Pal SK, Bernard-Tessier A, Grell P, et al.. A Phase I dose-escalation study of the HIF-2 alpha inhibitor DFF332 in patients with advanced clear-cell renal cell carcinoma. Clin Cancer Res. 2025, 31:1847-55. 10.1158\/1078-0432.CCR-24-2618","journal-title":"Clin Cancer Res"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1459","article-title":"HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma","volume":"26","author":"Courtney KD","year":"2020","unstructured":"Courtney KD, Ma Y, Diaz de Leon A, et al.. HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clin Cancer Res. 2020, 26:793-803. 10.1158\/1078-0432.CCR-19-1459","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/455540-belzutifan-in-von-hippel-lindau-syndrome-and-renal-cell-carcinoma-mechanisms-clinical-evidence-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:29:37Z","timestamp":1778934577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/455540-belzutifan-in-von-hippel-lindau-syndrome-and-renal-cell-carcinoma-mechanisms-clinical-evidence-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":64,"URL":"https:\/\/doi.org\/10.7759\/cureus.108967","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,16]]}}}